Lactobacillus rhamnosus GS066, bacteriocin, lyophilized powder, postbiotics and their application in inhibiting Helicobacter pylori
By fermenting and freeze-drying Lactobacillus rhamnosus GS066 and its bacteriocins, freeze-dried powder and postbiotics were prepared, solving the problem of poor inhibitory effect of probiotics on Helicobacter pylori in the existing technology. Effective inhibition of Helicobacter pylori and Escherichia coli was achieved, and it can be applied in the fields of pharmaceuticals, cleaning agents and food.
Patent Information
- Application Number
- CN202411154693.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-22
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-08-22
AI Technical Summary
Existing technologies are ineffective at inhibiting Helicobacter pylori infection, especially the bacteriocins from probiotics, which have poor inhibitory effects.
Freeze-dried powder and postbiotics were prepared using Lactobacillus rhamnosus GS066 and its extracted bacteriocins through specific fermentation and processing methods to inhibit Helicobacter pylori and Escherichia coli.
Lactobacillus rhamnosus GS066 and its bacteriocins have significant inhibitory effects on Helicobacter pylori and Escherichia coli. The freeze-dried powder and post-biotic contain high levels of live bacteria and can be stored stably for a long time. They can be used in pharmaceuticals, cleaning agents and food to regulate intestinal flora and maintain intestinal balance.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of microorganisms, and in particular relates to Lactobacillus rhamnosus GS066, bacteriocin, lyophilized powder, postbiotics and applications thereof in inhibiting Helicobacter pylori. Background Art
[0002] Helicobacter pylori ( Helicobacter pylori ,HP), often parasitizes in the gastric mucosal tissue, causing diseases such as chronic gastritis and peptic ulcer after infection. It is closely related to diseases such as gastric cancer and gastric mucosa-associated lymphoid tissue lymphoma, and is listed as a Class I biological carcinogen by the World Health Organization (WHO). Helicobacter pylori infection mainly includes long-term close contact with the infected person, using unclean eating utensils used by the infected person, etc. Spontaneous clearance of gastritis caused by Helicobacter pylori bacteria is relatively rare. Helicobacter pylori infection can be cured through standardized drug treatment, but if you do not pay attention to hygiene and living habits, you can still be infected again. Therefore, reasonable sterilization and cleaning of daily utensils, and taking effective drugs to treat Helicobacter pylori infection, are of positive significance for the prevention and treatment of Helicobacter pylori.
[0003] Probiotics have a certain auxiliary therapeutic effect on the treatment of Helicobacter pylori. Probiotics can improve intestinal flora, enhance body immunity, regulate gastrointestinal function, etc. Helicobacter pylori infection can inhibit the inflammatory response in the body to a certain extent and promote the recovery of gastrointestinal mucosa after taking probiotics. Bacteriocins are a class of polypeptides or precursor polypeptides with antibacterial activity produced by bacteria through ribosome synthesis mechanism during metabolism. They are a class of antibacterial substances that exist in the natural environment where bacteria live. Therefore, screening probiotics with the function of inhibiting Helicobacter pylori and extracting their bacteriocins for inhibiting Helicobacter pylori will help to achieve the prevention and treatment of Helicobacter pylori. Summary of the invention
[0004] In view of this, the object of the present invention is to provide Lactobacillus rhamnosus GS066, which can effectively inhibit Helicobacter pylori.
[0005] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:
[0006] Lactobacillus rhamnosus ( Lacticaseibacillus rhamnosus ) GS066, the rhamnosus Lactobacillus GS066 is deposited in the General Microbiology Center of China Microorganism Culture Collection Administration (CGMCC for short), with the deposit number CGMCC NO. 29393 and the deposit date: December 25, 2023.
[0007] Another object of the present invention is to provide a method for extracting bacteriocin, comprising the following steps: the rhamnosus Lactobacillus GS066 is inoculated in a liquid culture medium, fermented for 22-30 hours, the fermented liquid is centrifuged, the supernatant is collected, ammonium sulfate is added to the supernatant for precipitation, and the precipitate is collected by centrifugation to obtain bacteriocin.
[0008] Preferably, when the Lactobacillus rhamnosus GS066 is fermented for 12-18 hours, 0.3-1.0 g / L nicotinamide adenine dinucleotide phosphate is added to the fermentation system to continue the fermentation.
[0009] Another object of the present invention is to provide a preparation, which contains the Lactobacillus rhamnosus GS066 and / or the bacteriocin extracted by the method.
[0010] Another object of the present invention is a method for preparing a freeze-dried powder, comprising the following steps: the rhamnosus Lactobacillus GS066 is inoculated into a liquid culture medium, fermented until the glucose content in the fermentation liquid is ≤0.1 g / L, the fermentation liquid is centrifuged, the bacteria are collected and mixed with a freeze-drying protective agent to form an emulsion, and the emulsion is freeze-dried.
[0011] Preferably, the protective agent of the freeze-dried powder includes, by mass percentage, 8-12% skim milk powder, 7-9% trehalose, 1-3% mannitol, 0.08-0.12% Tween-80, 0.8-1.2% sodium glutamate, 0.04-0.06% vitamin C, and the balance is water.
[0012] Another object of the present invention is to provide freeze-dried powder prepared by the freeze-dried powder preparation method.
[0013] Another object of the present invention is to provide a method for preparing postbiotics, comprising the following steps: the rhamnosus Lactobacillus GS066 is inoculated into a liquid culture medium, and when fermented for 12-18 hours, 0.3-1.0 g / L of nicotinamide adenine dinucleotide phosphate is added to the fermentation system to continue fermentation, and after the fermentation is completed, the fermentation liquid is concentrated and dried to obtain the postbiotics.
[0014] Another object of the present invention is to provide postbiotics prepared by the postbiotic preparation method.
[0015] Another object of the present invention is to provide the use of the rhamnosus Lactobacillus GS066, the bacteriocin extracted by the method, the preparation, the lyophilized powder or the postbiotic in the preparation of a product for inhibiting Gram-negative bacteria, wherein the Gram-negative bacteria include Helicobacter pylori and Escherichia coli.
[0016] Compared with the prior art, the present invention has the following beneficial effects:
[0017] The present invention provides Lactobacillus rhamnosus GS066. Compared with commercially available strains of the same genus, Lactobacillus rhamnosus LGG and Lactobacillus rhamnosus HN001, the bacteriocin produced by the metabolism of the strain has good inhibition on Helicobacter pylori. Lactobacillus rhamnosus GS066 and bacteriocins extracted from the fermentation broth of the strain can effectively inhibit Gram-negative bacteria.
[0018] Biological Deposit Description
[0019] The Lactobacillus rhamnosus GS066 of the present invention is classified and named as Lactobacillus rhamnosus ( Lacticaseibacillus rhamnosus ), depository: China General Microbiology Center of Microbiological Culture Collection Administration (CGMCC for short), depository address: No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, deposit number: CGMCCNO. 29393, deposit date: December 25, 2023. DETAILED DESCRIPTION
[0020] The invention provides rhamnosus lactobacillus GS066. The rhamnosus lactobacillus is named as rhamnosus lactobacillus GS066 and is deposited in the General Microbiological Center of China National Committee for Microbiological Culture Collection with a deposit number of CGMCC NO.29393.
[0021] In the present invention, the Lactobacillus rhamnosus GS066 was isolated from infant feces and was identified as Lacticaseibacillus rhamnosus .
[0022] The present invention provides a method for extracting bacteriocin, comprising the following steps: the rhamnosus lactobacillus GS066 is inoculated in a liquid culture medium for fermentation, after fermentation for 22-30 hours, the fermentation liquid is obtained and centrifuged to collect the supernatant, ammonium sulfate is added to the supernatant for precipitation, and the precipitate is collected by centrifugation to obtain bacteriocin; preferably, when the rhamnosus lactobacillus GS066 is fermented for 12-18 hours, 0.3-1.0 g / L of nicotinamide adenine dinucleotide phosphate (NADP) is added to the fermentation system to continue fermentation. The bacteriocin extracted by the present invention can effectively inhibit Gram-negative bacteria, and the addition of NADP during the fermentation process can increase the content of bacteriocin in the fermentation liquid, further improving the inhibitory effect of bacteriocin on Gram-negative bacteria.
[0023] In the method for extracting bacteriocin of the present invention, the liquid culture medium is a modified MRS culture medium; the inoculation amount of the rhamnosus lactobacillus GS066 is 1%-5% of the mass of the fermentation system, preferably 3%; the fermentation temperature is 35-40°C, preferably 37°C; NADP is preferably added when the fermentation is carried out for 14-16 hours, and more preferably NADP is added when the fermentation is carried out for 15 hours; the added concentration of NADP is preferably 0.4-0.6 g / L, and more preferably 0.5 g / L; the added concentration of NADP is the working concentration of NADP; the fermentation time of the rhamnosus lactobacillus GS066 is preferably 24-28 hours, and more preferably Fermentation for 25h is selected; the centrifugal conditions of the fermentation broth are: 4°C, the centrifugal speed is 6000-10000rmp, preferably 8000rmp, the centrifugal time is 10-30min, preferably 20min; ammonium sulfate is added to the supernatant until the ammonium sulfate saturation in the solution is 60-80%, and the preferred ammonium sulfate saturation is 70%; after adding ammonium sulfate, stir at 25-30°C for 0.5h-2h, and the centrifugal conditions after stirring are: 4°C, the centrifugal speed is 6000-8000rmp, preferably 8000rmp, and the centrifugal time is 10-20min, preferably 15min. The precipitate collected by centrifugation in the present invention is bacteriocin, and as an practicable method, the bacteriocin is dried at 35-45°C.
[0024] The above-mentioned Lactobacillus rhamnosus GS066 of the present invention is activated before being inoculated into a liquid culture medium for fermentation, and the activation comprises inoculating Lactobacillus rhamnosus GS066 into a modified MRS culture medium, culturing at 36-38° C. for 18 hours, and then performing the above-mentioned activation culture twice to obtain a fermentation seed liquid. In the present invention, the inoculation amount of Lactobacillus rhamnosus GS066 is 1%-5% of the mass of the fermentation system, preferably 3%.
[0025] The invention can effectively increase the yield of bacteriocin by adding NADP into the fermentation system during the fermentation process of Lactobacillus rhamnosus GS066.
[0026] The present invention also provides a bacteriocin extracted by the above-mentioned method for extracting bacteriocin. When the bacteriocin is used, sterile water is added to dissolve it, and the bacteriocin can effectively inhibit Helicobacter pylori and Escherichia coli.
[0027] The present invention also provides a preparation, which contains the above-mentioned Lactobacillus rhamnosus GS066 and / or the bacteriocin. The preparation of the present invention can effectively inhibit Gram-negative bacteria and has excellent inhibitory effects on Helicobacter pylori and Escherichia coli.
[0028] The present invention also provides a method for preparing a freeze-dried powder, comprising the following steps: inoculating the rhamnosus Lactobacillus GS066 in a liquid culture medium, fermenting until the glucose content in the fermentation liquid is ≤0.1 g / L, centrifuging the fermentation liquid, collecting the bacteria and mixing them with a freeze-drying protective agent to form an emulsion, and freeze-drying the emulsion.
[0029] In the present invention, the lyophilization protective agent comprises, by mass percentage, 8-12% skim milk powder, 7-9% trehalose, 1-3% mannitol, 0.08-0.12% Tween-80, 0.8-1.2% sodium glutamate, 0.04-0.06% vitamin C, and the balance is water.
[0030] In the preparation method of the freeze-dried powder of the present invention, the liquid culture medium comprises: 25 g / L glucose, 8 g / L beef extract powder, 15 g / L yeast extract powder, 10 g / L bovine bone peptone, 2 g / L dipotassium hydrogen phosphate, 2 g / L diammonium hydrogen citrate, 5 g / L sodium acetate, 0.58 g / L magnesium sulfate, 0.25 g / L manganese sulfate, 1 g / L Tween-80, 0.5 g / L L-cysteine hydrochloride, and the pH value is 6.8; the culture medium is sterilized before use, and the sterilization conditions are: sterilization at 121° C. for 12-18 min, preferably 15 min; and when the liquid culture medium is cooled to 38-39° C., rhamnosus lactobacillus GS066 is inoculated.
[0031] In the preparation method of the freeze-dried powder of the present invention, the inoculation amount of the rhamnosus Lactobacillus GS066 is 1%-5% of the mass of the fermentation system, preferably 3%; the fermentation temperature is 35-40°C, preferably 37°C; the pH is controlled to be 4.8-5.2, preferably 5.0 during the culture process, and alkali-supplementing fermentation is performed; the conditions for centrifuging the fermentation liquid to collect the bacteria are: 4°C, the centrifugal speed is 6000-10000rmp, preferably 8000rmp, and the centrifugal time is 10-30min, preferably 20min; as an implementable manner, the emulsion formed by mixing the bacteria and the freeze-drying protective agent is placed in a vacuum freeze dryer for freeze drying, and the temperature curve of the freeze-drying agent is: -40°C is maintained for 4h, the temperature is increased by 5°C every 2h, the temperature is 0°C at the 24th hour, and then the temperature is increased by 3°C every 2h, and the final maximum temperature is 30°C and remains unchanged until the material is dried.
[0032] The present invention also provides a freeze-dried powder prepared by the freeze-dried powder preparation method, wherein the moisture content of the freeze-dried powder is less than 3%, and the water activity is 0.10-0.20aw. The number of viable Lactobacillus rhamnosus GS066 in the freeze-dried powder is ≥5.2×10 11 cfu / g.
[0033] The Lactobacillus rhamnosus GS066 of the present invention is prepared as a freeze-dried powder under the protection of a freeze-drying agent, has a high content of viable bacteria, and can be stably stored for a long time at 0-10°C.
[0034] The present invention also provides a preparation method of postbiotics, comprising the following steps: the rhamnosus Lactobacillus GS066 is inoculated into a liquid culture medium for fermentation, and when the fermentation is 12-18 hours, 0.3-1.0 g / L of nicotinamide adenine dinucleotide phosphate is added to the fermentation system to continue fermentation, and after the fermentation is completed, the fermentation liquid is concentrated and dried to obtain the postbiotics.
[0035] In the preparation method of postbiotics of the present invention, the liquid culture medium is: 15-25 g / L of glucose, 5-15 g / L of sucrose, 8-12 g / L of skim milk, and 10-30 g / L of wheat bran powder; as an practicable method, the culture medium is pasteurized, and the sterilization conditions are: the sterilization temperature is 75-85°C, and the sterilization time is 40-80 min. The inoculation amount of the rhamnosus lactobacillus GS066 is 1%-5% of the mass of the fermentation system, preferably 3%; the fermentation temperature is 35-40°C, preferably 37°C; NADP is preferably added when the fermentation is carried out for 14-16 hours, and more preferably NADP is added when the fermentation is carried out for 15 hours; the added concentration of the NADP is preferably 0.4-0.6 g / L, more preferably 0.5 g / L; the added concentration of the NADP is the working concentration of NADP; the fermentation of rhamnosus lactobacillus GS066 ends when the pH of the fermentation liquid no longer decreases; the concentration is carried out by reduced pressure evaporation concentration, and the concentration conditions are: vacuum degree 0.07-0.1 MPa, preferably 0.09 MPa, temperature 40-50°C, preferably 45°C; the drying is spray drying when the fermentation liquid is concentrated to one tenth of the original volume, and the spray drying conditions are: inlet air temperature is 165-175°C, preferably 170°C, and feed rate is 9.8-11.0 mL / min, preferably 10.4 mL / min.
[0036] The present invention also provides a postbiotic prepared by the postbiotic preparation method, wherein the content of bacteriocin in the postbiotic is ≥10.52 mg / g, and the postbiotic has a high content of bacteriocin, which can effectively inhibit Helicobacter pylori.
[0037] The present invention also provides the use of the Lactobacillus rhamnosus GS066, the bacteriocin, the preparation, the lyophilized powder or the postbiotic in preparing a product for inhibiting Gram-negative bacteria, wherein the Gram-negative bacteria include Helicobacter pylori and Escherichia coli.
[0038] The Lactobacillus rhamnosus GS066 and the bacteriocin extracted from the fermentation broth of Lactobacillus rhamnosus GS066 of the present invention can effectively inhibit Helicobacter pylori and Escherichia coli. The provided Lactobacillus rhamnosus GS066 freeze-dried powder has a high content of live bacteria, and the prepared postbiotics have a high content of bacteriocin, both of which can be effectively used to inhibit Helicobacter pylori and Escherichia coli.
[0039] The products described in the present invention include medicines, cleaning agents and foods. The medicines can be used to treat and / or prevent Helicobacter pylori infection; the cleaning agents can effectively inhibit Helicobacter pylori and Escherichia coli in the environment and reduce bacterial contamination; and the foods help regulate intestinal flora and maintain the balance of intestinal flora.
[0040] In a specific embodiment of the present invention, the MRS liquid culture medium comprises: 10.0 g / L peptone, 5.0 g / L beef extract powder, 4.0 g / L yeast extract powder, 20.0 g / L glucose, 5.0 g / L sodium acetate, 2.0 g / L dipotassium hydrogen phosphate, 2.0 g / L triammonium citrate, 0.05 g / L manganese sulfate, 0.2 g / L magnesium sulfate, and 1.0 g / L Tween-80.
[0041] Improved MRS liquid medium: peptone 10.0 g / L, beef extract powder 5.0 g / L, yeast extract powder 4.0 g / L, glucose 20.0 g / L, sodium acetate 5.0 g / L, dipotassium hydrogen phosphate 2.0 g / L, triammonium citrate 2.0 g / L, manganese sulfate 0.05 g / L, magnesium sulfate 0.2 g / L, L-cysteine hydrochloride 0.5 g / L, Tween-80 1.0 g / L.
[0042] Nutrient broth solid culture medium: peptone 10.0g / L, beef extract powder 3.0g / L, sodium chloride 5.0g / L, glucose 1.0g / L, agar 12.0g / L.
[0043] Nutrient broth medium: peptone 10.0 g / L, beef extract powder 3.0 g / L, sodium chloride 5.0 g / L, glucose 1.0 g / L.
[0044] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.
[0045] Example 1
[0046] Isolation and identification of Lactobacillus rhamnosus GS066
[0047] Fecal samples of healthy infants in Keshiketeng Banner, Inner Mongolia were collected and diluted 10 times with sterile saline at a mass concentration of 0.9%. The samples were diluted 3 times and spread on MRS solid medium. After culturing at 37°C for 72 hours, single colonies were picked and cultured until the strains were purified. The selected anaerobic strains were Gram-positive, and the catalase test, gelatin liquefaction test, motility test, indole test, and nitrate reduction test were performed. The strains with negative results in catalase, gelatin liquefaction, oxidase test, indole and nitrate test were selected. The strains were enriched and cultured in MRS liquid medium and preserved in 30% glycerol. The strains were identified as Lactobacillus rhamnosus by 16SrDNA of Sangon Biotech (Shanghai) Co., Ltd.
[0048] The rhamnosus Lactobacillus GS066 was inoculated into MRS medium and cultured at 37° C. for 24 h to obtain a bacterial liquid of the rhamnosus Lactobacillus GS066.
[0049] The standard strains of Escherichia coli ATCC 44102, Staphylococcus aureus ATCC 25923, and Helicobacter pylori ATCC 43504 were obtained from Shanghai Beinuo Biotechnology Co., Ltd.
[0050] Preparation method of Columbia blood plate: Mix BHI solid culture medium and Columbia agar in a ratio of 1:3, add 1L of water, divide into 500mL Erlenmeyer flasks, sterilize at 121℃ for 20min, cool to 50-55℃, add 5% sterile defibrinated sheep blood, mix well and pour onto the plate.
[0051] Inhibition of Helicobacter pylori experiment: Cool the mixed solid medium of Columbia and BHI to about 55°C, add 5 mL of sterile defibrinated sheep blood to 100 mL of medium, mix well, and then take 10 9 1 mL of Helicobacter pylori ATCC 43504 suspension with a concentration of 1×10 CFU / mL was added to the mixed medium, shaken evenly to avoid bubbles, and then quickly poured into the plate with the Oxford cup placed in advance. After the medium cooled and solidified, the Oxford cup was removed and 150 μL of Lactobacillus rhamnosus GS066 suspension (concentration was 1×10 8 CFU / mL), cultured at 37℃ microaerobic conditions for 72h, and the size of the inhibition zone was determined. Each treatment was repeated 3 times.
[0052] Escherichia coli ATCC 44102 and Staphylococcus aureus ATCC 25923 were inoculated into nutrient broth medium and cultured in a shaker at 37°C and 180 rpm for 24 hours for activation. The nutrient broth solid medium was cooled to about 55°C and 10 91 mL of Escherichia coli ATCC 44102 and Staphylococcus aureus ATCC 25923 suspension with CFU / mL was added to the mixed medium, shaken evenly to avoid bubbles, and then quickly poured into the plate with the Oxford cup placed in advance. After the medium cooled and solidified, the Oxford cup was removed and 150 μL of Lactobacillus rhamnosus GS066 bacterial solution (concentration was 1×10 8 CFU / mL), cultured at 37℃ microaerobic conditions for 72h, and the size of the inhibition zone was determined. Each treatment was repeated 3 times. The results are shown in Table 1.
[0053] Table 1 Inhibition zone
[0054]
[0055] As shown in Table 1, the bacterial liquid of Lactobacillus rhamnosus GS066 has inhibitory effects on both Helicobacter pylori ATCC 43504 and Escherichia coli ATCC44102.
[0056] Example 2
[0057] Extraction method of bacteriocin from Lactobacillus rhamnosus GS066
[0058] The frozen strain of Lactobacillus rhamnosus GS066 was inoculated into a freshly sterilized modified MRS medium at an inoculation rate of 3% of the mass of the fermentation system, and cultured at 37°C for 18 hours; the above fermentation liquid was inoculated into a freshly sterilized modified MRS medium at an inoculation rate of 3% of the mass of the fermentation system, and cultured at 37°C for 18 hours; the previous step was repeated to obtain a fermentation seed liquid.
[0059] The fermentation seed liquid was inoculated into the modified MRS medium at an inoculation amount of 3% of the fermentation system mass, and fermented at 37° C. for 24 h to obtain a fermentation liquid.
[0060] The fermentation liquid was centrifuged at 4°C and 8000 rpm for 20 min, and the supernatant after centrifugation was used for bacteriocin extraction. Ammonium sulfate was slowly added to the supernatant to make the ammonium sulfate saturation in the solution 70%, and magnetic stirring was performed at 25°C for 1 h at a stirring speed of 200 rpm. After the stirring was completed, the fermentation liquid was centrifuged at 4°C and 8000 rpm for 15 min, the supernatant was discarded, the precipitate was collected, and the bacteriocin was obtained by drying at 40°C.
[0061] Example 3
[0062] Extraction method of bacteriocin from Lactobacillus rhamnosus GS066
[0063] The frozen strain of Lactobacillus rhamnosus GS066 was inoculated into a freshly sterilized modified MRS medium at an inoculation rate of 3% of the mass of the fermentation system, and cultured at 37°C for 18 hours; the above fermentation liquid was inoculated into a freshly sterilized modified MRS medium at an inoculation rate of 3% of the mass of the fermentation system, and cultured at 37°C for 18 hours; the previous step was repeated to obtain a fermentation seed liquid.
[0064] The fermentation seed liquid was inoculated into the modified MRS medium at an inoculation amount of 3% of the fermentation system mass, fermented at 37° C. for 15 h, NADP with a working concentration of 0.5 g / L was added, and fermentation was continued for 10 h to obtain the fermentation liquid.
[0065] The fermentation liquid was centrifuged at 4°C and 8000 rpm for 20 min, and the supernatant after centrifugation was used for bacteriocin extraction. Ammonium sulfate was slowly added to the supernatant to make the ammonium sulfate saturation in the solution 70%, and magnetic stirring was performed at 25°C for 1 h at a stirring speed of 200 rpm. After the stirring was completed, the fermentation liquid was centrifuged at 4°C and 8000 rpm for 15 min, the supernatant was discarded, the precipitate was collected, and the bacteriocin was obtained by drying at 40°C.
[0066] Example 4
[0067] Effects of bacteriocins from different strains on inhibiting Helicobacter pylori
[0068] For Lactobacillus acidophilus LA-5 (purchased from Chr. Hansen, Denmark), Lactobacillus plantarum ST-III (Bright Plant Vitality Lactic Acid Bacteria Isolation), Lactobacillus rhamnosus LGG (purchased from Chr. Hansen, Denmark), Lactobacillus rhamnosus HN001 (purchased from DuPont, USA), and Lactobacillus rhamnosus GS066, bacteriocins were extracted using the method provided in Example 2. According to the weight of the bacteriocin obtained by drying, a 0.2 mg / mL bacteriocin solution was prepared with sterile water for the Helicobacter pylori inhibition experiment.
[0069] The standard strains of Escherichia coli, Staphylococcus aureus and Helicobacter pylori are the same as those in Example 1.
[0070] Columbia blood plate preparation method: same as Example 1.
[0071] Preparation of Helicobacter pylori strains: streak the Helicobacter pylori glycerol tube onto Columbia blood agar plates and culture them in a 37°C three-gas incubator for 3-5 days. The composition ratio of the three-gas incubator is: 85% N2, 10% CO2, and 5% O2. After a single colony appears, pick a single colony and streak it densely onto Columbia blood agar plates again. Culture them in a 37°C three-gas incubator for 3-5 days. Collect the agar plates with 3-5 mL PBS and adjust the concentration to 10 9 CFU / mL, and detect the number of viable bacteria.
[0072] Inhibition of Helicobacter pylori experiment: Cool the mixed solid medium of Columbia and BHI to about 55°C, add 5 mL of sterile defibrinated sheep blood to 100 mL of medium, mix well, and then take 10 9 1 mL of Helicobacter pylori suspension with a CFU / mL was added to the above-mentioned mixed culture medium, shaken evenly to avoid bubbles, and then quickly poured into a plate with an Oxford cup placed in advance. After the culture medium was cooled and solidified, the Oxford cup was taken out, and 200 μL of 0.2 mg / mL bacteriocin solution prepared from five strains of Lactobacillus acidophilus LA-5, Lactobacillus plantarum ST-Ⅲ, Lactobacillus rhamnosus LGG, Lactobacillus rhamnosus HN001, and Lactobacillus rhamnosus GS066 were injected into each well, respectively. MRS liquid culture medium was set as a blank control, and the plate was lightly covered and placed upright in a 37°C three-gas incubator for culture for 3 days, and the diameter of the inhibition zone was measured with a vernier caliper. Three parallels were made for each bacterium.
[0073] Escherichia coli and Staphylococcus aureus were inoculated into nutrient broth medium and cultured in a shaker at 37°C and 180 rpm for 24 h for activation. The nutrient broth solid medium was cooled to about 55°C and 10 9 1 mL of Escherichia coli and Staphylococcus aureus suspensions with CFU / mL were added to the above-mentioned mixed culture medium, shaken evenly to avoid bubbles, and then quickly poured into a plate with an Oxford cup placed in advance. After the culture medium was cooled and solidified, the Oxford cup was taken out, and 200 μL of 0.2 mg / mL bacteriocin solution prepared from five strains of Lactobacillus acidophilus LA-5, Lactobacillus plantarum ST-Ⅲ, Lactobacillus rhamnosus LGG, Lactobacillus rhamnosus HN001, and Lactobacillus rhamnosus GS066 were injected into each well, respectively. MRS liquid culture medium was set as a blank control, and the plate was lightly covered and placed upright in a 37°C three-gas incubator for culture for 3 days, and the diameter of the inhibition zone was measured with a vernier caliper. Three parallels were made for each bacterium. The results are shown in Table 2.
[0074] Table 2 Antibacterial effect of bacteriocin
[0075]
[0076] As shown in Table 2, the bacteriocin solutions of the same concentration prepared by the five strains all have an inhibitory effect on Helicobacter pylori, among which the bacteriocin produced by the metabolism of Lactobacillus rhamnosus GS066 has the best inhibitory effect on Helicobacter pylori, followed by Lactobacillus rhamnosus HN001, and Lactobacillus plantarum ST-Ⅲ has the worst effect; the five strains have a good inhibitory effect on Escherichia coli, among which Lactobacillus rhamnosus GS066 has the best inhibitory effect, and Lactobacillus plantarum ST-Ⅲ has the worst effect; the five strains have no inhibitory effect on Staphylococcus aureus. It can be seen that the bacteriocins of the five strains have significant inhibitory effects on Gram-negative bacteria, but poor inhibitory effects on Gram-positive bacteria.
[0077] Example 5
[0078] Effect of Bacteriocin Extraction Methods on Bacteriocin Yield of Lactobacillus rhamnosus GS066
[0079] The method of implementing 3 for extracting bacteriocins was adopted. NADP with a working concentration of 0.5 g / L was added to rhamnosus casei GS066 at different fermentation periods (no addition, 0 h, 5 h, 10 h, 15 h, 20 h). After adding NADP, the fermentation was continued until 25 h after fermentation after inoculation of rhamnosus casei GS066. The fermentation broth was centrifuged and bacteriocins were extracted from the supernatant. According to the weight of the bacteriocin obtained by drying, a 0.2 mg / mL bacteriocin solution was prepared with sterile water for the Helicobacter pylori inhibition experiment. The results are shown in Table 3.
[0080] Table 3 Results of inhibiting Helicobacter pylori
[0081]
[0082] As shown in Table 3, there is no difference in the bacteriocin produced when 0.5 g / L nicotinamide adenine dinucleotide phosphate is added or not added at 0 h, 5 h, 10 h, and 20 h. The present invention can produce more bacteriocins when added at 15 h of fermentation. After repeated experimental analysis, around 15 h, Lactobacillus rhamnosus GS066 enters the stable period and the bacteria enters the secondary metabolism. At this time, adding a certain concentration of nicotinamide adenine dinucleotide phosphate can promote the large-scale production of bacteriocins; 0 h, 5 h, and 10 h are the bacterial growth period, and 20 h is the bacterial decay period, which has no effect on the production of bacteriocins.
[0083] Example 6
[0084] Preparation of freeze-dried powder of Lactobacillus rhamnosus GS066
[0085] Fermentation medium: glucose 25g / L, beef extract powder 8g / L, yeast extract powder 15g / L, bovine bone peptone 10g / L, dipotassium hydrogen phosphate 2g / L, diammonium hydrogen citrate 2g / L, sodium acetate 5g / L, magnesium sulfate 0.58g / L, manganese sulfate 0.25g / L, Tween-801g / L, L-cysteine hydrochloride 0.5g / L.
[0086] The freeze-drying protective agent composition is: water 70%, skim milk powder 10%, trehalose 8%, mannitol 2%, Tween-80 0.1%, sodium glutamate 1%, vitamin C 0.05%.
[0087] After the medium is prepared, the pH value is adjusted to 6.8, sterilized at 121°C for 15 minutes, and when cooled to 38°C, inoculated with 3% of the fermentation system mass of Lactobacillus rhamnosus GS066, and the fermentation tank is inoculated and cultured. The culture temperature is 37°C, and the pH value is controlled at 5.0 for alkali supplementation fermentation. When the residual glucose in the fermentation liquid is 0.1g / L, the fermentation is stopped.
[0088] The fermentation liquid was centrifuged in a low-temperature centrifuge at a temperature of 4°C, a rotation speed of 8000 rpm, and a time of 20 min to collect the bacteria, and the obtained bacteria were fully mixed with the freeze-drying protective agent to form an emulsion.
[0089] The fully mixed emulsion was placed in a vacuum freeze dryer for freeze drying. The temperature curve of the freeze dryer was: -40°C for 4 hours, the temperature was increased by 5°C every 2 hours, the temperature was 0°C at the 24th hour, and then the temperature was increased by 3°C every 2 hours, and the final maximum temperature was 30°C and kept constant until the material was dried to obtain the lyophilized powder of Lactobacillus rhamnosus GS066. The moisture content of the lyophilized powder was less than 3%, and the water activity was 0.10-0.20aw.
[0090] The obtained freeze-dried Lactobacillus rhamnosus GS066 powder was tested to have a viable count of 5.2×10 11 cfu / g.
[0091] Example 7
[0092] Preparation of postbiotics from Lactobacillus rhamnosus GS066
[0093] Liquid culture medium: glucose 20g / L, sucrose 10g / L, skim milk 10g / L, wheat bran powder (passed through 800 mesh sieve) 20g / L.
[0094] After the culture medium is prepared, it is pasteurized at 80°C for 60 minutes. When it is cooled to 37°C, rhamnosus Lactobacillus GS066 is inoculated at an inoculation amount of 3% of the fermentation system mass for fermentation culture. The culture temperature is 37°C. At 15 hours, 0.5 g / L NADP is added and fermentation is continued for 9 hours. When the pH value of the fermentation liquid no longer decreases, the fermentation is terminated.
[0095] The fermentation liquid was concentrated by vacuum concentration, and evaporated and concentrated at a vacuum degree of 0.09 MPa and a temperature of 45°C, and spray dried when the fermentation liquid was concentrated to one tenth. The spray drying conditions were an inlet air temperature of 170°C and a feed rate of 10.4 mL / min, and the postbiotics of Lactobacillus rhamnosus GS066 were obtained.
[0096] Take the postbiotics of Lactobacillus rhamnosus GS066 and dissolve them in purified water. According to the solid-liquid ratio of the postbiotic liquid fermentation medium of 1:16.7, the postbiotics and purified water are mixed at a mass ratio of 1:16.7 to extract bacteriocins. At the same time, bacteriocins are extracted from the fermentation broth before concentration. The bacteriocin extraction method adopts the method provided in Example 3. The extracted bacteriocins are tested for inhibiting Helicobacter pylori. The results are shown in Table 4.
[0097] Table 4 Antibacterial effect
[0098]
[0099] As shown in Table 4, after the fermentation of Lactobacillus rhamnosus GS066 postbiotics is completed, the bacteriocin contained in the fermentation broth is 0.64 mg / mL, which is consistent with the content after the preparation of the postbiotics, and has the same inhibitory effect on Helicobacter pylori. It can be seen that the Lactobacillus rhamnosus GS066 postbiotics have a good inhibitory effect on Helicobacter pylori.
[0100] Example 8
[0101] Experiment on the inhibition of Helicobacter pylori by Lactobacillus rhamnosus GS066 in mice
[0102] A total of 95 SPF-grade C57BL / 6 (4-week-old, female) mice were selected as experimental animals. After one week of normal feeding, mixed antibiotics (10 mg / mL ampicillin, 2 mg / mL gentamicin, and 25 mg / mL azithromycin per mouse) were gavaged for 3 days, and then 10 mice were separated as the control group, and the remaining mice were used for modeling.
[0103] Modeling: gavage 0.3 mL of bacterial solution with a concentration of 1×10 9 CFU / mL of Helicobacter pylori suspension was gavaged every other day for a total of 5 times to prepare a Helicobacter pylori infection model. Five mice were randomly selected, and their stomachs were dissected and removed. The stomachs were tested for Hp colonization using a gastric Helicobacter pylori pH indicator diagnostic kit, and the inner material of the gastric mucosa was cultured and passaged. Hp growth that could be stably passaged was detected in all of them, indicating that the model was successfully established.
[0104] After the model was successfully established, the mice were divided into 9 groups, including model group, positive control group, high-dose lyophilized powder group, medium-dose lyophilized powder group, low-dose lyophilized powder group, high-dose postbiotic group, medium-dose postbiotic group, low-dose postbiotic group and unmodeled control group, with 10 mice in each group.
[0105] Among them, the freeze-dried powder in this embodiment is obtained by the method of Example 6, and the postbiotics are obtained by the method provided in Example 7.
[0106] All mice were gavaged with the same dose of 0.3 mL of drugs. The gavage drugs and cycles are shown in Table 5.
[0107] Table 5 Gavage drugs and cycles
[0108]
[0109] After 40 days of treatment, the mice were killed by cervical dislocation and the stomach and intestine were examined as follows:
[0110] (1) Take gastric tissue sections and stain according to the instructions of the Hp staining kit (provided by Fuzhou Maixin Biotechnology Development Co., Ltd.) to observe the grade of gastric Hp infection. Hp appears dark red and the background is red. Hp-: no Hp (<2 red dots); Hp+: a small amount of Hp locally (2-10 red dots); Hp++: 10-50 red dots; Hp+++: >50 red dots.
[0111] (2) Take 500 mg of mouse gastric mucosal tissue, homogenize it and centrifuge it to obtain the supernatant. Use mouse ELISA kit (Lianke Biotechnology Co., Ltd.) to measure the content of IL-1β, IL-8, IFN-γ, IL-4 and IL-10 in mouse gastric mucosa. The specific steps are carried out according to the instructions.
[0112] (3) DNA was extracted using a DNA extraction kit (Tiangen Biochemical Bacterial Genomic DNA Extraction Kit (DP302)). The operation was performed according to the instructions of the kit, and the purity, concentration and integrity of the total DNA obtained from the intestinal part were tested. The highly variable V3-V4 region of the bacterial 16SrRNA gene was selected for PCR amplification: upstream primer 338F (SEQ ID NO.1): ACTCCTACGGGAGGCAGCAG, downstream primer 806R (SEQ ID NO.2): GGACTACHVGGGTWTCTAAT, and the amplified product was 280 bp. Three PCR replicates were performed for each sample, and the three replicate PCR products were mixed and the products were detected by 2% agarose gel electrophoresis. The PCR products were purified using the (Tiangen Biochemical DNA Product Purification Kit (DP205)) kit, and the purity was detected by 2% agarose gel electrophoresis. The PCR products were quantified using the QuantiFluor-ST blue fluorescence quantification system, and then mixed in the corresponding proportions according to the sequencing requirements of each sample. The library was constructed using the NEXTFLEX Rapid DNA-Seq kit, and sequencing was performed using the Illumina Miseq PE300 platform.
[0113] The original sequencing sequence was quality controlled using fastp0.20.0 software (https: / / github.com / OpenGene / fastp), and spliced using FLASH1.2.7 software (http: / / www.cbcb.umd.edu / software / flash). The sequence quality was quality controlled and filtered at the same time. After distinguishing the samples, taxonomic unit (OTU) cluster analysis and species taxonomy analysis were performed. Based on the results of OTU cluster analysis, the diversity, abundance, coverage and other information of species in the community can be obtained through α diversity index analysis, among which the Shannon index can reflect the diversity of the community, the Chao index can reflect the abundance of the community, and the cover-age index can reflect the coverage of the community. The sequencing depth was further tested, and community structure analysis was performed at each taxonomic level based on taxonomic information, followed by species composition analysis, LEfSe (http: / / huttenhower.sph.harvard.edu / galaxy / root?tool_id=lefse_upload) multi-level species difference discrimination analysis, and COG functional annotation (http: / / hutten hower.sph.harvard.edu / gal-axy / root?tool_id=PICRUSt_normalize).
[0114] (1) Comparison of H. pylori infection in gastric tissue of mice in each group
[0115] Table 6 Comparison of Hp infection in gastric tissue of mice in each group
[0116]
[0117] Note: Compared with the blank group, a P <0.05; compared with the model group, b P <0.05.
[0118] The number of animals with Hp infection in gastric tissue of mice in the model group was significantly increased compared with that in the control group; compared with the model group, the number of animals with Hp infection in gastric tissue of mice in the positive control group and the 6 groups of mice experimented with the freeze-dried powder of the present invention and postbiotics was significantly reduced, and the differences were statistically significant.
[0119] (2) Contents of IL-1β, IL-8, IFN-γ, IL-4, and IL-10 in gastric mucosa of mice in each group
[0120] Table 7 Contents of IL-1β, IL-8, IFN-γ, IL-4 and IL-10 in gastric mucosa
[0121]
[0122] Note: Compared with the control group, # P <0.05,## P <0.01; compared with the model group, * P <0.05,** P <0.01.
[0123] As shown in Table 7, compared with the control group, the IL-1β, IL-8, and IFN-γ in the model group increased significantly after establishment, with significant differences ( P <0.01), the IL-1β, IL-8, and IFN-γ of the six groups of experiments using the freeze-dried powder of the present invention and postbiotics were significantly different from those of the model group ( P <0.01); compared with the model group, the IL-4 and IL-10 indicators in the experimental group 6 were significantly different ( P <0.01). This shows that after the modeling is successful, taking the live bacteria preparation of Lactobacillus rhamnosus GS006 and postbiotics can reduce the inflammatory response caused by Helicobacter pylori.
[0124] (3) Analysis of intestinal flora of mice in each group
[0125] Table 8 Analysis results of α-diversity of intestinal flora in each group of mice
[0126]
[0127] Note: Compared with the control group, # P <0.05,## P <0.01; compared with the model group, * P <0.05,** P <0.01.
[0128] According to the results in Table 8, compared with the control group, the Shannon index and Chao index of the model group were both reduced ( P <0.01), the coverage index of the model group increased ( P <0.05); Compared with the model group, the Shannon index and Chao index of the six groups using the freeze-dried powder of the present invention and postbiotics for experiments were increased, and the difference was significant ( P <0.05 or P <0.01), the coverage index of the high and medium dose groups in the experimental group decreased ( P <0.05). It can be seen that Lactobacillus rhamnosus GS066 plays a good regulatory role on the intestinal flora of mice in the Helicobacter pylori model.
[0129] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. Lactobacillus rhamnosus ( Lacticaseibacillus rhamnosus ) GS066, characterized in that, The Lactobacillus rhamnosus GS066 is deposited in the General Microbiology Center of the China Microbiological Culture Collection Administration, with the deposit number being CGMCC NO. 29393.
2. A preparation, characterized in that The preparation contains the Lactobacillus rhamnosus GS066 according to claim 1.
3. A freeze-dried powder, characterized in that: The preparation method of the freeze-dried powder comprises the following steps: inoculating the rhamnosus Lactobacillus GS066 described in claim 1 into a liquid culture medium, fermenting until the glucose content in the fermentation liquid is ≤0.1 g / L, centrifuging the fermentation liquid, collecting the bacteria and mixing them with a freeze-drying protective agent to form an emulsion, and freeze-drying the emulsion.
4. The freeze-dried powder according to claim 3, characterized in that Calculated by mass percentage, the protective agent of the freeze-dried powder includes: 8-12% skim milk powder, 7-9% trehalose, 1-3% mannitol, 0.08-0.12% Tween-80, 0.8-1.2% sodium glutamate, 0.04-0.06% vitamin C, and the balance is water.
5. A postbiotic, characterized in that: The preparation method of the postbiotic comprises the following steps: the rhamnosus Lactobacillus GS066 described in claim 1 is inoculated into a liquid culture medium, and when fermented for 12-18 hours, 0.3-1.0 g / L of nicotinamide adenine dinucleotide phosphate is added to the fermentation system to continue fermentation, and after the fermentation is completed, the fermentation liquid is concentrated and dried to obtain the postbiotic.
6. Use of the Lactobacillus rhamnosus GS066 according to claim 1, the preparation according to claim 2, the lyophilized powder according to claim 3 or 4, or the postbiotic according to claim 5 in the preparation of a drug for inhibiting Helicobacter pylori.
Citation Information
Patent Citations
Composite microbiological antibiotic and preparation method thereof
CN101524180A
Lactobacillus plantarum and bacteriocins produced by lactobacillus plantarum and capable of inhibiting Gram negative bacteria
CN101812414A
Lactobacillus plantarum M503, preparation compounded by lactobacillus plantarum M503 and lactobacillus rhamnosus and application of lactobacillus plantarum M503 and lactobacillus rhamnosus in anti-helicobacter pylori medicine
CN115029265A
Lactobacillus rhamnosus with antagonistic effect on helicobacter pylori
CN116875480A
Lactobacillus reuteri and application thereof in preparation of medicine for preventing and treating vaginitis
CN117683691A
Cited By
Bifidobacterium breve BD003 and application of compound bacterial powder of bifidobacterium breve BD003 in digestion aiding and bowel relaxing
CN122503281A
